Arnon Rosenthal, Ph.D., is a distinguished neuroscientist and entrepreneur who co-founded ALECTOR INC., where he serves as the Chief Executive Officer. With a robust background in neuroscience and biotechnology, Dr. Rosenthal has dedicated his career to advancing therapeutic solutions for neurodegenerative diseases. Prior to ALECTOR, he held pivotal roles at companies like Rinat Neuroscience and Genentech, where he led research efforts that contributed to the development of several successful biopharmaceutical products. His academic journey began at the Weizmann Institute of Science in Israel, where he earned his Ph.D., followed by postdoctoral work at MIT and the Salk Institute. At ALECTOR INC., Dr. Rosenthal has been instrumental in steering the company towards its mission of developing immunotherapies to combat neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases. Under his leadership, ALECTOR has grown into a pioneering biotech firm, securing significant funding and forming strategic partnerships with major pharmaceutical companies. His vision for the company is rooted in the belief that modulating the immune system can unlock new treatments for previously intractable diseases. Dr. Rosenthal's strategic oversight has been crucial in advancing ALECTOR’s pipeline of innovative therapies through various stages of clinical trials. Dr. Rosenthal’s achievements extend beyond his corporate leadership. He is an active member of the scientific community, contributing to numerous peer-reviewed publications and serving on advisory boards for various organizations focused on neurodegenerative research. His work has been recognized with several awards, reflecting his impact on the field. As CEO of ALECTOR, Dr. Rosenthal continues to drive the company forward, guided by his passion for translating cutting-edge science into meaningful treatments that can improve the lives of patients worldwide.